MidAtlantic Bio Angel and NewYorkBIO Forge Strategic Partnership for 2025
New York, NY (April 23, 2025) – Mid Atlantic Bio Angels Group (MABA) and NewYorkBIO announced today a strategic partnership, bringing together two leading organizations dedicated to supporting innovation, driving investment, and accelerating growth across New York’s life science ecosystem.
The partnership affirms a shared mission to promote early-stage life science innovation, conduct scientific due diligence, and generate value for members and the broader ecosystem. Both organizations will work to bridge the gap between promising life science innovations and investment capital.
“NewYorkBIO plays a critical role in supporting early-stage life science companies and helping them navigate the complex path from innovation to impact,” said Yaniv Sneor, founder of MABA. “Their commitment to startups aligns seamlessly with MABA’s mission of identifying and investing in promising life science ventures. We are proud to welcome NewYorkBIO as a valued partner.”
Through the partnership, MABA and NewYorkBIO will work closely together to support each organization through access to events, member networks, and funding applicants. In addition, the partnership will garner promotion across organizational platforms and communications to support increased engagement throughout the life science industry and increase engagement.
“At NewYorkBIO, we are dedicated to partnering with leaders such as MABA to collaborate and support the groundbreaking discoveries and innovations that New York’s ecosystem is constantly developing,” said NewYorkBIO CEO Jennifer Hawks Bland. “At a time when funding resources are uncertain, collaboration between the life science and finance industries is crucial in ensuring companies can continue their innovative work to develop the treatments and cures of tomorrow.”
The MABA and NewYorkBIO partnership reflects both organizations’ shared commitment to building a more collaborative ecosystem for life sciences.
Mid Atlantic Bio Angels (MABA)
Mid Atlantic Bio Angels group (bioangels.net) is a life science angel investor group focused exclusively on new and emerging therapeutics, devices, diagnostics, and digital health companies, with no geographic limitations. Membership in MABA is by invitation only and is extended to active, accredited investors, as well as institutional investors and pharma and device companies wishing to invest alongside the angels. MABA’s members include practicing physicians, executives within small and large life science companies, and corporate members from the industry. MABA also manages Sidecar Fund II, a co-investment fund providing access to MABA’s curated deal flow, for non-MABA members.
About NewYorkBIO
As the leading advocate for the life science community in New York, NewYorkBIO brings together hundreds of New York’s bioscience companies, universities, research institutions, and others dedicated to advancing life science research and commercializing treatments and cures for patients. NewYorkBIO connects key voices and companies of all sizes with resources to initiate and support transformative change to impact patient outcomes. Learn more at https://www.newyorkbio.org/
